ClinicalTrials.gg
Not yet recruitingNCT07116928GLOW-CKDUpdated Nov 18, 2025

Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

A Phase 4 interventional study of ganagliflozin and Placebo in T2DM (Type 2 Diabetes Mellitus) and CKD - Chronic Kidney Disease, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,244
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Diabetes Mellitus, Type 2 by Huadong Medicine Co., Ltd. — 7 open to participants now, 7 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Huadong Medicine Co., Ltd..

Planned enrollment
Largest of 10
1,244 · median 395
Started
2025
with 4 others
Phase 4
2 of 10
2 open now
Registered
5th of 10
by date

Among the 10 studies in Diabetes Mellitus, Type 2 by Huadong Medicine Co., Ltd., this one has the largest planned enrollment, is one of 5 that started in 2025, is one of 2 in phase 4, and was the 5th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 10 studies in Diabetes Mellitus, Type 2 by Huadong Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Diabetes Mellitus, Type 2 by Huadong Medicine Co., Ltd., or all of them as a file.
02

Study summary

This study aims to investigate the impact of adding Ganagliflozin tablets to the current background therapy on preventing the progression of kidney disease in subjects with type 2 diabetes and chronic kidney disease. The efficacy and safety will be evaluated by comparing the effects of Ganagliflozin tablets and placebo tablets added to the current background treatment over 120 weeks

Read the detailed description

A phase IV clinical study on the efficacy and safety of Ganagliflozin in treating patients with type 2 diabetes and chronic kidney disease (multicenter, randomized, double-blind, placebo parallel controlled). 1244 subjects all received a stable dose of ACEi or ARB for at least 4 weeks before enrollment.

Efficacy assessment: Compared with the placebo group, time to the first occurrence of kidney disease progression and the changes in eGFR slope, UACR, and score of KDQOL-36 were evaluated.

03

Conditions studied

  • T2DM (Type 2 Diabetes Mellitus)
  • CKD - Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female individuals aged 18 years and above;
  • Meets the diagnostic criteria for T2DM;
  • Meets the diagnostic criteria for CKD, during the screening period( Formula): eGFR ≥ 30 to \< 60 mL/min/1.73m\^2, and UACR is ≥ 30 to \< 5000 mg/g; Or eGFR ≥ 60 to \< 90 mL/min/1.73m\^2, and UACR is ≥ 300 to \< 5000 mg/g ;
  • ≥ 6.5% to ≤ 12%;
  • If there are no or special instructions, all subjects must take a stable dose of ACEi or ARB at least 4 weeks before randomization;

Exclusion criteria

Exclusion Criteria:

  • Patients with type 1 diabetes or other special types of diabetes;
  • A medical history or clinical evidence indicating that the subjects have other primary kidney diseases and secondary kidney diseases other than type 2 diabetes (including but not limited to lupus nephritis, ANCA-related nephritis);
  • History of kidney transplantation;
  • Blood potassium level > 5.5 mmol/L during the screening period.
  • (NYHA) classification of grade IV during the screening period;
  • Experienced ketoacidosis, myocardial infarction, unstable angina pectoris, stroke, (TIA), hospitalization due to heart failure, or hospitalization due to urinary tract infection or acute kidney injury within 12 weeks before the screening period;
  • Receiving ACEi and ARB in combination;
  • Receiving mineralocorticoid receptor antagonists (MRA) or direct renin inhibitors (DRI) within 8 weeks before randomization;
  • Receiving drugs with effects (such as cyclophosphamide, cyclosporine A, tacrolimus, etc.) or biological agents (rituximab, belimumab, etc.) during the 12 weeks before the screening period;
  • Receiving SGLT-2 inhibitors or GLP-1 receptor agonists within 8 weeks before the screening, or have previously used SGLT-2 inhibitor drugs and discontinued due to poor efficacy.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,244 participants (estimated)

Study arms

  • Experimental
    ganagliflozin

    50 mg Once daily, 120 weeks

    Drug: ganagliflozin

  • Placebo comparator
    placebo

    50 mg Once daily, 120 weeks

    Drug: Placebo

Interventions

  • 50 mg Once daily, 120 weeks

  • DrugPlacebo

    50 mg Once daily, 120 weeks

06

What researchers measure

Primary outcomes

  1. The average change in eGFR as measured by the total slope of eGFR from baseline to week 120

    Time frame: Baseline to Week 120

Secondary outcomes

  1. Time to the first occurrence of kidney disease progression

    The progression of kidney disease is defined as: 1. maintenance dialysis or 2. receipt of a kidney transplant or 3. sustained decline in eGFR to \< 15 mL/min/1.73m\^2 or 4. a sustained decline of ≥ 40% in eGFR from baseline or 5. doubling of serum creatinine or 6. renal death

    Time frame: from baseline to Week 120

  2. The proportion of subjects with a total slope of eGFR greater than -3 mL/min/1.73 m²/year from baseline to week 120

    Time frame: from baseline to week 120

  3. The average change in eGFR as measured by the total slope of eGFR from baseline to week 2 and week 8,from week 2 and week 8 to week 120

    Time frame: from baseline to week 2 and week 8,from week 2 and week 8 to week 120

  4. The changes in urine albumin-to-creatinine ratio (UACR) at each visit compared to the baseline

    Time frame: from baseline to week 120

  5. Changes in the scores of the Kidney Disease Quality of Life-36 Scale (KDQOL-36) compared to the baseline

    The higher the score, the better the patient's quality of life related to CKD

    Time frame: from baseline to week 120

  6. Changes in the scores of the European Five-Dimensional Health Scale (EQ-5D-5L) compared to the baseline

    Higher the score means the better quality of life

    Time frame: from baseline to week 120

Other outcomes

  1. time to the first occurrence of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure

    Time frame: from baseline to week 120

  2. Changes in liver stiffness measurement (LSM) of liver transient elastography

    Time frame: from baseline to week 52 and 120

  3. change in the staging of diabetic retinopathy measured by non-mydriatic fundus photography

    Time frame: from baseline to week 52 and 120

  4. Changes in control attenuation index (Cap) of liver transient elastography

    Time frame: from baseline to week 52 and 120

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2025; primary completion for Oct 2031, 71 months later.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's planned 71 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2025
First posted
Aug 12, 2025
StartEst.
Nov 30, 2025
Primary completionEst.
Oct 30, 2031
CompletionEst.
Dec 30, 2031
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07116928
Responsible party
Sponsor
First posted
Aug 12, 2025
Start date
Nov 30, 2025 (estimated)
Primary completion
Oct 30, 2031 (estimated)
Completion
Dec 30, 2031 (estimated)
Last update
Nov 18, 2025

Study contacts

Xiaofen Qian
Contact
qianxiaofen@eastchinapharm.com
+86-0571-89908582
Wanting Zhang
Contact
zhangwanting@eastchinapharm.com
+86-0571-89905517

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Janagliflozin

Start the discussion